NCT05467748View on ClinicalTrials.gov

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 13, 2025

Primary Completion Date

October 13, 2027

Study Completion Date

October 12, 2029

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Tulmimetostat

combination of oral tazemetostat and intravenous pembrolizumab treatment for patients with advanced non-small cell lung cancer

Trial Locations (1)

77030-4211

Michael E. DeBakey VA Medical Center, Houston, TX, Houston

All Listed Sponsors
collaborator

VA Greater Los Angeles Healthcare System

FED

lead

VA Office of Research and Development

FED